Head and Neck Neoplasms  >>  Tecentriq (atezolizumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NCT02543645: A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Checkmark Initiation of enrollment in P1/2 trial in combination with varlilumab in renal cell carcinoma
Dec 2015 - Dec 2015: Initiation of enrollment in P1/2 trial in combination with varlilumab in renal cell carcinoma
Checkmark MPDL3280A in combination with varlilumab for RCC
Aug 2015 - Aug 2015: MPDL3280A in combination with varlilumab for RCC
Terminated
1
18
US
Combination of Varlilumab and Atezolizumab
Celldex Therapeutics, Genentech, Inc.
Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
04/17
05/17
NCT01375842 / 2011-001422-23: A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Checkmark SITC 2015
Nov 2015 - Nov 2015: SITC 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Update at AACR 2015
More
Completed
1
661
US, Europe
Atezolizumab, MPDL3280A
Genentech, Inc.
Tumors, Hematologic Malignancies
09/18
09/18

Download Options